proteomics

People with myalgic encephalomyelitis/chronic fatigue syndrome can wait years for diagnoses; biomolecular tests are finally in development.

Advances in computation and artificial intelligence help scientists identify novel antibiotics encoded within human proteins and create new ones.

While some pediatric brain cancers have known genetic causes, many do not. Three-dimensional profiling revealed new disease mechanisms and drug targets.

Advances in data integration enable scientists to combine multiomics data and a patient’s clinical record to develop precision medicine approaches for treating disease.

COVID-19 has gotten a little better at infecting cells and dodging antibodies with each set of mutations in new variants. Omicron is the best at dodging antibodies, but its modified structure sacrificed virulence for antibody resistance.

Researchers identified common, dysregulated pathways among different cancers using a newly developed protein-protein interaction mapping technique. The results may inform treatment and lead to the development of more effective drugs for cancer.

LIVE October 22nd, 2021 at 9:30 AM ET 

Klaus Pantel and Christoffer Beghardt will discuss advances in early cancer biomarker detection and its clinical implications.

LIVE August 26th, 2021 at 11:00 AM ET

In this webinar, experts will discuss new approaches to identify small therapeutic candidates targeting diabetes and Alzheimer’s disease.

Researchers combined genome, phenotype, and proteome-wide association assays to identify protein variants associated with severe COVID-19, providing clues for how these proteins may contribute to disease.

Targeting oncogenic transcription factors like MYC is challenging, but researchers found a way to target its regulator, WDR5, for degradation, exemplifying the capacity of protein degraders to target the “undruggable.”